Activity Description
Hypertrophic cardiomyopathy (HCM) affects up to 1 in 200 people and poses distinct challenges for heart failure specialists—especially when patients develop symptomatic obstructive HCM (oHCM). Traditional therapies aim to manage symptoms and reduce sudden cardiac death risk, but often fall short of addressing the underlying disease. Variable patient responses and unequal access to specialty care further complicate long-term management. Cardiac myosin inhibitors (CMIs) represent a novel, targeted treatment that alters the disease’s pathophysiology, offering new avenues to improve outcomes.
This PeerView educational activity—based on a symposium during the 2025 HFSA Annual Scientific Meeting—is tailored for heart failure specialists. Through interactive, case-based learning, leading HCM experts explore diagnostic strategies, emerging evidence, and the integration of CMIs into practice. If you missed the live session, access the on-demand version to strengthen your clinical skills and enhance care for patients with oHCM.